Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 2014. The report serves as a notification of transactions involving Directors and Persons Discharging Managerial Responsibility (PDMRs) regarding their holdings in American Depositary Shares (ADSs).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share transaction details.
- Transaction Price: $53.606 per ADS.
- Transaction Date: July 14, 2014.
- Transaction Type: Re-investment of dividends paid on July 10, 2014.
Material Changes
The filing details increases in personal holdings for specific directors and connected persons resulting from dividend re-investment. No material changes to the company's financial position or operations are reported in this document.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is a regulatory compliance notification regarding insider trading rules (Disclosure and Transparency Rules 3.1.4R(1)(a) and (c)).
Investor Verification Points
- Verify the specific number of ADSs acquired by Dr. M M Slaoui (1,703.570) and other listed directors.
- Confirm the dividend payment date of July 10, 2014, and the subsequent re-investment execution on July 14, 2014.
- Note that this filing does not contain financial performance data for the period.